Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Presentation on the biosimilar Enoxaparin of ROVI
Mon, 13/03/2017 - 10:46
0 min
ENOXAPARIN BIOSIMILAR.png
Download related document
Select rating
Give Presentation on the biosimilar Enoxaparin of ROVI 1/5
Give Presentation on the biosimilar Enoxaparin of ROVI 2/5
Give Presentation on the biosimilar Enoxaparin of ROVI 3/5
Give Presentation on the biosimilar Enoxaparin of ROVI 4/5
Give Presentation on the biosimilar Enoxaparin of ROVI 5/5
No votes yet
Related
ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and...
Madrid, 12 March 2024 Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, ROVI), informs of the agreement that has been concluded with...
3 min
12/03/2024
Full Year 2023 Results Press Release
ROVI ACHIEVED OPERATING REVENUE GROWTH OF 1% IN THE FIRST POST-PANDEMIC YEAR Operating revenue increased 1% to 829.5 million euros in...
4 min
27/02/2024
First nine months 2023 results press release
ROVI REPORTS OPERATING REVENUE GROWTH OF 3% FOR THE FIRST NINE MONTHS OF THE FIRST POST-PANDEMIC YEAR Operating revenue increased 3%...
5 min
08/11/2023
See More
Email
Facebook
Twitter
LinkedIn
ENOXAPARIN BIOSIMILAR.png